Tremfya

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process.** If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4**.**

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*cm*

Drug Information:

*Strength/Measure*_____ *Units* ❑ ml ❑ Gm ❑ mg ❑ ea ❑ Un

*Directions(sig)*_____ *Route of administration*_____

*Dosing frequency*_____

Send completed form to: Priority Partners Fax: 1-866-212-4756

Site of Service Questions:

A. Indicate the site of service requested:
- ❑ On Campus Outpatient Hospital (22)
- ❑ Off Campus Outpatient Hospital (19)
- ❑ Home (12), *skip to Criteria Questions*
- ❑ Office (11), *skip to Criteria Questions*
- ❑ Ambulatory Surgical Center (24), *skip to Criteria Questions*

B. Is the patient less than 18 years of age?
- ❑ Yes, *skip to Clinical Criteria Questions*
- ❑ No

C. Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, other pre- medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.*** ❑ Yes, *skip to Clinical Criteria Questions* ❑ No

D. Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?
ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.
❑ Yes, *skip to Clinical Criteria Questions* ❑ No

E. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
❑ Yes, *skip to Clinical Criteria Questions* ❑ No

F. Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
❑ Yes, *skip to Clinical Criteria Questions* ❑ No

G. Has the patient's home been deemed not eligible or appropriate for home infusion services by a home infusion provider? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
❑ Yes, *skip to Clinical Criteria Questions* ❑ No

H. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting?
ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation. ❑ Yes ❑ No

Clinical Criteria Questions:

1. What is the diagnosis?
   - ❑ Plaque psoriasis
   - ❑ Psoriatic arthritis WITH co-existent plaque psoriasis
   - ❑ Psoriatic arthritis WITHOUT co-existent plaque psoriasis
   - ❑ Other _____
2. What is the ICD-10 code? _____
3. Will the requested drug be used in combination with any other biologic (e.g., Humira) or targeted synthetic disease-modifying anti-rheumatic drug (DMARD) (e.g., Olumiant, Otezla, Xeljanz)? ❑ Yes ❑ No
4. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic DMARD (e.g., Olumiant, Xeljanz)? ❑ Yes ❑ No *If Yes, skip to #6*
5. Has the patient had a tuberculosis (TB) test (e.g., tuberculosis skin test [PPD], an interferon-release assay [IGRA], or a chest x-ray) within 6 months of initiating therapy? ❑ Yes ❑ No *If Yes, skip to #8*

6. Does the patient have risk factors for tuberculosis (TB) (e.g., persons with close contact to people with infectious TB disease; persons who have recently immigrated from areas of the world with high rates of TB [e.g., Africa, Asia, Eastern Europe, Latin America, Russia]; children less than 5 years of age who have a positive TB test; groups with high rates of TB transmission [e.g., homeless persons, injection drug users, persons with HIV infection], or persons who work or reside with people who are at an increased risk for active TB [e.g., hospitals, long-term care facilities, correctional facilities, homeless shelters])? ❑ Yes ❑ No *If No, skip to Diagnosis section*

7. Has the patient been tested for tuberculosis (TB) within the previous 12 months? ❑ Yes ❑ No

8. What were the results of the tuberculosis (TB) test?
   ❑ Positive for TB
   ❑ Negative for TB, *skip to Diagnosis section*
   ❑ Unknown

9. Does the patient have latent or active tuberculosis (TB)? ❑ Latent ❑ Active ❑ Unknown

10. Has treatment for latent tuberculosis (TB) infection been initiated or completed?
    ❑ Yes – treatment initiated
    ❑ Yes – treatment completed
    ❑ No

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Plaque Psoriasis

11. Has the patient been diagnosed with moderate to severe plaque psoriasis? ❑ Yes ❑ No

12. Is this request for continuation of therapy with the requested drug? ❑ Yes ❑ No *If No, skip to #17*

13. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program?
    ❑ Yes, *skip to #17*
    ❑ No
    ❑ Unknown, *skip to #17*

14. Has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?
    ❑ Yes ❑ No

15. Has the patient experienced a reduction in body surface areas (BSA) affected from baseline? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of decreased body surface area affected.*** ❑ Yes ❑ No *If Yes, skip to #23*

16. Has the patient experienced an improvement in signs and symptoms of the condition from baseline (e.g., itching, redness, flaking, scaling, burning, cracking, pain)? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of improvement in signs and symptoms.*** ❑ Yes ❑ No *If Yes, skip to #23*

17. Has the patient ever received (including current utilizers) Otezla or a biologic indicated for the treatment of moderate to severe plaque psoriasis? ***ACTION REQUIRED: If 'Yes', attach chart notes, medical record documentation, or claims history supporting previous medications tried.*** ❑ Yes ❑ No *If Yes, skip to #23*

18. Are crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) affected? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of affected areas and body surface area affected.*** ❑ Yes ❑ No *If Yes, skip to #23*

19. What is the percentage of body surface area (BSA) affected (prior to starting the requested medication)? ***ACTION REQUIRED: Please attach chart notes or medical record documentation of affected areas and body surface area affected.***
    - ❑ Greater than or equal to 3% to less than 10% of BSA
    - ❑ Greater than or equal to 10% of BSA, *skip to #23*
    - ❑ Less than 3% of BSA

20. Has the patient experienced an inadequate response, or has an intolerance to phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine or acitretin? ***ACTION REQUIRED: If 'Yes', please submit chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy.*** ❑ Yes ❑ No *If Yes, skip to #23*

21. Does the patient have a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine and acitretin? ***ACTION REQUIRED: If 'Yes', please submit documentation of clinical reason to avoid therapy.***
    ❑ Yes ❑ No

22. Please indicate clinical reason to avoid pharmacologic treatment.
    - ❑ Clinical diagnosis of alcohol use disorder, alcoholic liver disease or other chronic liver disease
    - ❑ Breastfeeding
    - ❑ Cannot be used due to risk of treatment-related toxicity
    - ❑ Drug interaction
    - ❑ Pregnancy or currently planning pregnancy
    - ❑ Significant comorbidity prohibits use of systemic agents (e.g., liver or kidney disease, blood dyscrasias, uncontrolled hypertension)
    - ❑ Other _____

23. Is the patient currently receiving Tremfya? ❑ Yes ❑ No *If No, skip to #26*

24. Does the prescribed dose exceed 100 mg? ❑ Yes ❑ No

25. Is the prescribed frequency for the maintenance dose more frequent than one dose every 8 weeks?
    ❑ Yes ❑ No *If Yes or No, no further questions*

26. Does the prescribed dose exceed a loading dose of 100 mg at weeks 0 and 4 and a maintenance dose of 100 mg thereafter? ❑ Yes ❑ No

27. Is the prescribed frequency for the maintenance dose more frequent than one dose every 8 weeks? ❑ Yes ❑ No

<u>Section B: Psoriatic Arthritis WITH or WITHOUT Co-Existent Plaque Psoriasis</u>

28. Has the patient been diagnosed with active psoriatic arthritis (PsA)? ❑ Yes ❑ No

29. Is this request for continuation of therapy with the requested drug? ❑ Yes ❑ No *If No, skip to #33*

30. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program?
    - ❑ Yes, *skip to #33*
    - ❑ No
    - ❑ Unknown, *skip to #33*

31. Has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?
    ❑ Yes ❑ No

32. Has the patient experienced improvement in any of the following from baseline? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response. [Note to CRU: Please select all that apply.]***
    - ❑ Number of swollen joints, *skip to #34*
    - ❑ Dactylitis, *skip to #34*
    - ❑ Enthesitis, *skip to #34*
    - ❑ Skin and/or nail involvement, *skip to #34*
    - ❑ Number of tender joints, *skip to #34*
    - ❑ None of the above

33. Is the patient currently receiving Tremfya? ❑ Yes ❑ No *If No, skip to #36*

34. Does the prescribed dose exceed 100 mg? ❑ Yes ❑ No

35. Is the prescribed frequency for the maintenance dose more frequent than one dose every 8 weeks? ❑ Yes ❑ No *If Yes or No, no further questions*

36. Does the prescribed dose exceed a loading dose of 100 mg at weeks 0 and 4 and a maintenance dose of 100 mg thereafter? ❑ Yes ❑ No

37. Is the prescribed frequency for the maintenance dose more frequent than one dose every 8 weeks? ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.

X_____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Priority Partners Fax: 1-866-212-4756